
    
      Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced
      hepatocellular carcinoma.No study has evaluated the efficacy and safety of lenvatinib in
      unresectable intrahepatic cholangiocarcinoma. Thus, the investigators carried out this
      prospective study to find out it.
    
  